BioSpace News Archive

Psilocybin Clinical Trial Sponsored by Clairvoyant Therapeutics Reaches 90% Randomization

Clairvoyant Therapeutics Inc. , today announced that it is on target to potentially become the first in the world to commercialize clinically validated psilocybin treatment.

April 3, 2024
·
3 min read
BioCapital

Medcura Closes $22.4 Million Financing to Accelerate Development of Surgical Hemostatic Gel and Surgical Hemostasis Portfolio

Medcura, Inc. today announced that it has closed a private placement with aggregate gross proceeds of US $22.4 million (the “Offering”) in Convertible Debt.

April 3, 2024
·
3 min read
BioCapital

CF Foundation Provides Up to $8.5M to SpliSense to Support a Clinical Trial for a Potential Treatment for Splicing Mutations

The Cystic Fibrosis Foundation is investing up to $8.5 million in additional funds in SpliSense to continue clinical trials for its inhaled antisense oligonucleotide (ASO) drug for people with cystic fibrosis.

April 3, 2024
·
2 min read
Pharm Country

Milestone Scientific Commences Sales of CompuFlo® Epidural Disposables within PRC Alliance Pain Relief Center in Ormond Beach, Florida

Milestone Scientific Inc. today announced that it has commenced sales of CompuFlo ® Epidural disposables into PRC Alliance Pain Relief Center at Ormond Beach, Florida.

April 3, 2024
·
4 min read
CMUH (Taiwan) Launches “Intelligent Sepsis Early Prediction System (ISEPS),” Detecting Sepsis in One Minute Only

In conventional practice, a blood culture report wouldn’t be available until 18 to 72 hours later, rendering it non-feasible to facilitate rapid response.

April 3, 2024
·
2 min read
Lone Star Bio

Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

Genprex, Inc. today announced that through its collaboration agreement with a large network of integrated, community-based oncology practices, the Company has added multiple clinical trial sites for its Acclaim-3 clinical study of Reqorsa® Immunogene Therapy.

April 3, 2024
·
8 min read
Business

Asahi Kasei Medical and AW Technologies enter exclusive distribution agreement for TrachFlush in Japan

AW Technologies and Asahi Kasei Medical, a core operating company of the Asahi Kasei Group, have entered into an exclusive distribution agreement in Japan for AW Technologies’ TrachFlush™ device.

April 3, 2024
·
3 min read
Biotech Bay

Surrozen Publishes Study in ‘Respiratory Research’ Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis

Surrozen, Inc. (Nasdaq: SRZN) announced today publication of data in Respiratory Research highlighting the potential for Surrozen’s Wnt mimetic technologies to treat serious lung diseases like idiopathic pulmonary fibrosis (IPF) https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-024-02786-2.

April 3, 2024
·
8 min read
BioCapital

Study Shows hTERT Vaccination Induces Immunological Responses and Prevents Progression in a Subset of Therapy-Resistant Poor Prognosis Cancer Patients

In a significant stride towards active immune therapy of cancer, a recently featured article in Experimental Biology and Medicine (Volume 249, Issue 1) describes a Phase 1 clinical trial, led by James Spicer and colleagues at King’s College London.

April 3, 2024
·
2 min read
BioMidwest

LIB Therapeutics To Participate in Piper Sandler Virtual Cardio Day Focused on Highlights from ACC 2024 Conference

LIB Therapeutics Inc. today announced that David Cory, CEO, and Evan Stein, MD, PhD, COO / CSO, will participate in a virtual fireside chat at the Piper Sandler Virtual Cardio Day on April 10, 2024 at 10:30 AM ET.

April 3, 2024
·
2 min read